Senolytic Drug Navitoclax Reduces Heart Failure Symptoms and Cardiac Fibrosis
New study shows clearing senescent cells with Navitoclax improves heart function and reduces inflammation in heart failure with preserved ejection fraction.
Summary
Researchers tested whether clearing senescent (aged, damaged) cells could improve heart failure with preserved ejection fraction (HFpEF), a common condition with no effective treatments. Using a rat model of HFpEF, they found that senescent immune and endothelial cells accumulate in blood and heart tissue, driving inflammation and cardiac fibrosis. Treatment with Navitoclax, a senolytic drug that selectively kills senescent cells, reduced inflammation markers, improved kidney function, decreased fluid buildup in lungs, and reduced cardiac fibrosis. The study also found that HFpEF patients had more senescent white blood cells, which correlated with disease severity markers.
Detailed Summary
Heart failure with preserved ejection fraction (HFpEF) affects millions but lacks effective treatments. This comprehensive study investigated whether cellular senescence—the accumulation of aged, damaged cells that secrete inflammatory factors—drives HFpEF progression and whether clearing these cells could provide therapeutic benefit.
Researchers used ZSF1-Obese rats, which develop HFpEF through metabolic dysfunction, and tracked senescent cell accumulation from 12 weeks (pre-disease) through 20 weeks (established HFpEF). They found significant increases in senescent immune cells (p16+ leukocytes increased 2.5-fold) and endothelial cells in both blood and heart tissue compared to lean controls. These senescent cells correlated with elevated inflammatory markers including IL-6, TNF-α, and endothelial damage markers.
Treatment with Navitoclax (a BCL-2 inhibitor senolytic) at two timepoints—preventively at 12 weeks or therapeutically at 16 weeks—produced remarkable improvements. BNP levels (a key heart failure marker) decreased by approximately 40% in treated animals. Cardiac fibrosis was significantly reduced, with collagen deposition dropping by 35-50% depending on treatment timing. Pulmonary edema decreased substantially, and kidney function improved as measured by reduced creatinine and BUN levels.
Crucially, the researchers validated their findings in human patients with HFpEF, showing that circulating senescent leukocytes correlated positively with NT-proBNP levels and other disease severity markers. Flow cytometry revealed that HFpEF patients had 2-3 times more p16+ and p21+ senescent immune cells compared to healthy controls.
The study suggests senescent cell accumulation creates a vicious cycle: metabolic stress induces senescence, senescent cells secrete inflammatory factors (SASP), which damages the microvasculature and promotes fibrosis, further impairing cardiac function. Navitoclax breaks this cycle by selectively eliminating senescent cells while preserving healthy tissue. The therapeutic window appears broad, with benefits seen even when treatment began after HFpEF establishment, suggesting potential for treating existing disease rather than just prevention.
Key Findings
- Senescent immune cells increased 2.5-fold in HFpEF rats compared to controls (p<0.001)
- Navitoclax treatment reduced BNP levels by approximately 40% in treated animals
- Cardiac fibrosis decreased by 35-50% with senolytic treatment depending on timing
- Pulmonary edema was significantly reduced in Navitoclax-treated groups
- HFpEF patients had 2-3 times more senescent leukocytes than healthy controls
- Senescent cell levels correlated positively with NT-proBNP and disease severity markers
- Kidney function improved with senolytic treatment as measured by reduced creatinine and BUN
Methodology
Researchers used ZSF1-Obese rats (n=8-12 per group) as an established HFpEF model, tracking disease from 12-20 weeks of age. Navitoclax was administered at 50mg/kg for 3 consecutive days either preventively (12 weeks) or therapeutically (16 weeks). Human validation included 45 HFpEF patients and 20 controls. Senescent cells were identified using p16, p21, and SA-β-gal markers via flow cytometry and immunofluorescence. Statistical analysis used appropriate parametric and non-parametric tests with significance set at p<0.05.
Study Limitations
The study used a single animal model which may not fully recapitulate human HFpEF complexity. Human validation was limited to biomarker correlations without intervention data. One author (T.T.) holds shares in Unity Biotechnology, a senolytic company, representing a potential conflict of interest. Long-term safety and optimal dosing of Navitoclax in HFpEF patients remains to be established through clinical trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.